CagriSema
Semaglutide + cagrilintide combo in Phase 3 trials. Strongest weight loss data of any injectable to date, surpassing semaglutide alone through dual appetite/satiety targeting.
Key Facts
- ClassificationPeptide — Next-gen dual semaglutide + amylin analog with strongest weight loss data.
- Primary BenefitsFat Loss (10/10) · Gut Health (3/10)
- AdministrationInjection
- Typical Dose2.4 mg semaglutide + 2.4 mg cagrilintide weekly subq. Titrate slowly over several months.
- Evidence StrengthEmerging · Community sentiment 7/10
Quick Facts
- From price
- Not stocked
- Type
- peptide
- Administration
- Injection
- Evidence
- emerging
- Studies referenced
- 0
- Community sentiment
- 7/10
- Stacks with
- 0 peptides
Top benefits
Dosing
2.4 mg semaglutide + 2.4 mg cagrilintide weekly subq. Titrate slowly over several months.
Benefit Profile
Not yet in our tracked vendor supply.
CagriSema is still moving from clinical pipeline to research-chemical supply in the channels we monitor. We'll add pricing + vendor rows here as soon as a reference vendor carries it in stock. In the meantime, the mechanism and research summary on this page reflect published data only — not a purchase recommendation.
Questions about access routes? See our sourcing reference.
Related 🔥 Fat Loss Peptides
Other peptides strong in fat loss
GLP-1 drug (Ozempic/Wegovy) that suppresses appetite and burns fat.
Tirzepatide10/10Dual GLP-1/GIP drug (Mounjaro/Zepbound). Strongest weight loss peptide available.
Retatrutide10/10Triple-action weight loss drug hitting GLP-1, GIP, and glucagon receptors.
Survodutide9/10Dual GLP-1/glucagon weight loss peptide from Boehringer Ingelheim.
Mazdutide9/10Dual GLP-1/glucagon receptor drug with strong weight loss results.
Orforglipron9/10First oral non-peptide GLP-1 agonist in late-stage trials.